15,660 Shares in Globus Medical, Inc. $GMED Bought by Maverick Capital Ltd.

Maverick Capital Ltd. bought a new position in shares of Globus Medical, Inc. (NYSE:GMED) during the 1st quarter, Holdings Channel.com reports. The firm bought 15,660 shares of the medical device company’s stock, valued at approximately $1,349,000.

A number of other institutional investors have also recently made changes to their positions in the stock. Advisory Services Network LLC acquired a new position in shares of Globus Medical in the third quarter worth approximately $26,000. EverSource Wealth Advisors LLC boosted its holdings in Globus Medical by 74.3% in the second quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after acquiring an additional 197 shares during the last quarter. SBI Securities Co. Ltd. increased its position in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after purchasing an additional 167 shares during the period. Parallel Advisors LLC increased its position in Globus Medical by 45.1% during the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after purchasing an additional 173 shares during the period. Finally, Headlands Technologies LLC raised its holdings in Globus Medical by 485.4% during the 2nd quarter. Headlands Technologies LLC now owns 761 shares of the medical device company’s stock worth $45,000 after purchasing an additional 631 shares during the last quarter. Institutional investors own 95.16% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on GMED shares. Stifel Nicolaus dropped their price target on shares of Globus Medical from $95.00 to $80.00 and set a “hold” rating on the stock in a research report on Wednesday, July 8th. Zacks Research cut shares of Globus Medical from a “strong-buy” rating to a “hold” rating in a research report on Monday, July 6th. Truist Financial lowered their target price on shares of Globus Medical from $115.00 to $100.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. Needham & Company LLC boosted their target price on shares of Globus Medical from $114.00 to $117.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Wall Street Zen cut shares of Globus Medical from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Two equities research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $103.75.

Globus Medical Price Performance

Shares of GMED opened at $78.27 on Tuesday. Globus Medical, Inc. has a one year low of $51.79 and a one year high of $101.40. The company has a market cap of $10.62 billion, a PE ratio of 18.20, a P/E/G ratio of 1.58 and a beta of 0.95. The stock has a 50-day moving average of $79.77 and a 200-day moving average of $85.92.

Globus Medical (NYSE:GMED) last posted its quarterly earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping analysts’ consensus estimates of $0.92 by $0.20. The business had revenue of $759.85 million for the quarter, compared to the consensus estimate of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue for the quarter was up 27.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.68 EPS. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. Analysts expect that Globus Medical, Inc. will post 4.74 EPS for the current fiscal year.

Insider Buying and Selling at Globus Medical

In other news, Director David D. Davidar sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 5th. The stock was sold at an average price of $80.76, for a total transaction of $2,019,000.00. Following the transaction, the director directly owned 510,175 shares of the company’s stock, valued at $41,201,733. This represents a 4.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 18.38% of the stock is owned by insiders.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.